“We strive to explore and research every opportunity that will increase the quality of various DAR products, from foods to medicines to cosmetics, ultimately enhancing the lives of consumers worldwide.”
San Bruno, CA (PRWEB) January 25, 2011
China Health Resource, Inc. (OTCBB: CHRI), a leading Chinese pharmaceutical company specializing in producing, processing and commercializing Dahurian Angelica Root (DAR), today announced the company has officially received exclusive license to use and manage “Sichuan Angelica” from the Sui Ning Baizhi Association of Sichuan Province.
CHRI is a Traditional Chinese Medicine (TCM) enterprise in DAR production in Sichuan Province, where the majority of the company’s planting is based. Because DAR production takes place within the scope of the geographically protected region, the Company has received the exclusive license to use and manage “Sichuan Angelica” by the General Administration of Quality Supervision, Inspection and Quarantine of People’s Republic of China (http://www.AQSIQ.gov.cn) and the Sui Ning Baizhi Association of Sichuan Province.
Suining City in Sichuan Province is named as the “Hometown of Chinese Angelica”, with more than 600 years of Angelica-planting history. The geographical indication protection of Sichuan Province was approved to use “Sichuan Angelica”, with national brand protection including 22 towns in Suining City.
“Securing exclusive rights to the ‘Sichuan Angelica’ further signifies what CHRI has set out to do from the beginning,” stated Jiayin Wang, CEO. “We strive to explore and research every opportunity that will increase the quality of various DAR products, from foods to medicines to cosmetics, ultimately enhancing the lives of consumers worldwide.”
Currently, “Sichuan Angelica” of Suining City has become a well-known brand, with its annual output occupying more than 70% in the native Angelica market. In 2009, the China Agriculture Regional Brand Forum, hosted by the Ministry of Agriculture of the People’s Republic of China and undertaken by Zhejiang University, carried out the agricultural region brand valuation, and “Sichuan Angelica” ranked within the top 200, valued at 103 million yuan (approximately US$15 million).
China Health Resource Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.
Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.
For more information, please contact: China Health Resource, Inc., 343 Suining Zhong Road, Suining, Sichuan, P.R.China, . Tel: +86-825-239-1788, Web Site: http://www.ChinaHealthResource.com.